The focus of new agents for treating this malignancy has been on patients with relapsed or refractory disease, which carries a poor prognosis and short life expectancy.
Newer drugs are more targeted than standard agents, but their incorporation into treatment regimens is challenging because of the risk of cardiovascular and infectious adverse events.